Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Win Trial: Nivolumab and Ipilimumab in IBC
NCT02892734Phase 2Terminated
- Sponsor
- Northwestern University
- Start
- Sep 2017
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in inflammatory breast cancer (IBC), sponsored by Northwestern University. Primary endpoint: Progression Free Survival at 2 years. Started Sep 2017; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT02892734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02892734.